Benzinga | Jan 11, 2021 07:19AM EST

Deciphera Pharma Provides 2021 Goals

- Top-line Data for INTRIGUE Pivotal Phase 3 Study of QINLOCK(r) in Patients with Second-line GIST Expected in the Second Half of 2021

- Potential European Medicines Agency Approval of QINLOCK for Patients with Fourth-line GIST in the Second Half of 2021

- Company Planning to Finalize Pivotal Development Plans for Both Vimseltinib (DCC-3014) and Rebastinib in Second Half of 2021